---
title: "Neurocrine Biosciences (NBIX): news, pipeline and catalysts"
url: "https://aibio.space/companies/neurocrine-biosciences/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Neurocrine Biosciences news for investors: Neurocrine develops and sells drugs for neurological, psychiatric and endocrine disorders, led by Ingrezza for…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Neurocrine now has three products and much less cash

Neurocrine went from one big product to three since late 2024, and the $2.9 billion Soleno purchase left it with $481.7 million of cash and a $1.0 billion undrawn revolver. Growth is strong, but expenses are rising faster than Ingrezza sales and the largest product faces pricing pressure from Medicare negotiation. The 2027 Phase 3 readouts in depression and schizophrenia are the next clinical test.

Read the full desk view

aibio.space Investor Rank · Opinion

**7** /10 Positive view

Three growing first-in-class drugs, but the Soleno purchase cut cash to $481.7 million and Ingrezza faces Medicare pricing pressure; key phase 3 data come in 2027.

- **Technology**: 2/2

- **Odds**: 1/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Three marketed first-in-class drugs.** Ingrezza, Crenessity and Vykat XR produced $954 million of product sales in Q2, with muscarinic and depression candidates in Phase 3.

- **Odds**: **Strong commercial odds, open clinical ones.** Crenessity and Vykat XR are growing, but the 2027 depression and schizophrenia readouts face base rates of 57.8% for Phase 3 to filing across all diseases.

- **Balance sheet**: **Cash was spent on Soleno.** Cash and securities fell to $481.7 million at June 30 from $2.54 billion, with a $1.0 billion undrawn revolver.

- **Main risk**: **Ingrezza concentration and Medicare pricing.** About three-quarters of product revenue comes from one drug whose main competitor now has a lower negotiated Medicare price.

- **Watch next**: **Q3 results, then 2027 data.** The third-quarter report shows the first full quarter of Vykat XR, and Phase 3 readouts for osavampator and direclidine are due in 2027.

## Top news on Neurocrine

## Dates

**Quarter ending Sept. 30, 2026 (10-Q)**
Third-quarter report: first full quarter of Vykat XR sales; filing of CMO Eiry Roberts' employment agreement [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm)

**2027**
Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm)

**Exemption through 2027**
Ingrezza's small biotech exception from Medicare price negotiation selection runs until 2027 (price applicability year 2029 if selected) [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)

## The money

$481.7 million in cash, cash equivalents and marketable securities at June 30, 2026 (down from $2.54 billion at Dec. 31, 2025 after the Soleno acquisition). $1.0 billion revolving credit facility undrawn at June 30. The 10-Q says resources should be sufficient for at least the next 12 months. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)

Q2 2026 total revenue $959 million (up 39%): Ingrezza $716 million, Crenessity $184 million, Vykat XR $54 million from May 18. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm)

## Risks on the record

- Ingrezza is about three-quarters of product revenue; the 10-Q says lower negotiated prices for competitor Austedo may increase pricing pressure and affect formulary coverage. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)
- Cash fell from $2.54 billion to $481.7 million in six months after the $2.9 billion Soleno acquisition; the $1.0 billion revolver carries leverage and interest-coverage covenants. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)
- Chief medical officer replaced on Sept. 28, 2026, about 16 months after the previous change, ahead of two 2027 Phase 3 readouts; the 8-K gives no reason. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Neurocrine Biosciences?

7 out of 10, our positive view. Three growing first-in-class drugs, but the Soleno purchase cut cash to $481.7 million and Ingrezza faces Medicare pricing pressure; key phase 3 data come in 2027. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### How much did Neurocrine pay for Soleno Therapeutics?

Neurocrine paid $53.00 per share in cash, a total equity value of $2.9 billion, announced April 6, 2026. The deal closed May 18 after holders of 88.9% of Soleno's shares tendered. Cash paid, net of cash acquired, was $2.36 billion. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)

### What is Neurocrine's 2026 Ingrezza sales guidance?

On July 30, 2026 Neurocrine raised 2026 Ingrezza net sales guidance to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion. Second-quarter Ingrezza sales were $716 million, up 15%. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm)

### When are Neurocrine's Phase 3 results due?

Neurocrine's CEO said the company expects Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia in 2027. Both are in the company's Phase 3 programs described in the second-quarter release. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm)

### Who is Neurocrine's chief medical officer?

Eiry W. Roberts, M.D., was appointed chief medical officer effective Sept. 28, 2026, succeeding Sanjay Keswani, M.D. She held the role before Keswani, who took over on June 2, 2025. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm)

### How much cash does Neurocrine have after the Soleno deal?

Neurocrine had about $481.7 million in cash, cash equivalents and marketable securities at June 30, 2026, down from $2.54 billion at year-end 2025. It also had $1.0 billion of undrawn borrowing capacity under a revolving credit facility. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)

### What is Neurocrine Biosciences's market cap?

We do not publish live share prices. In its annual report, Neurocrine Biosciences, Inc. put the market value of shares held by non-affiliates (public float) at $9.52 billion as of Jun 30, 2025. Source

### Is Neurocrine Biosciences a smaller reporting company?

SEC records list Neurocrine Biosciences, Inc.'s filer category as: Large accelerated filer. Source

### Where is Neurocrine Biosciences headquartered?

SEC records list its business address as 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130. Source

### When does Neurocrine Biosciences's fiscal year end?

Neurocrine Biosciences, Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Neurocrine Biosciences last file with the SEC?

Its most recent filing in our record is an 8-K filed 2026-09-28. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm)

### What industry is Neurocrine Biosciences in?

Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source

## Legal and investor matters

Checked against Neurocrine Biosciences filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

The legal matters note in the 10-Q filed 2026-07-31 describes the Ingrezza Sprinkle patent suits against Zydus, the Soleno securities class action (filed against Soleno, now a Neurocrine subsidiary) and a DOJ civil investigative demand. It does not describe a securities class action or derivative suit naming Neurocrine itself. [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)

1. 2026-05-18 Other Neurocrine completes $53 per share cash acquisition of Soleno Therapeutics Neurocrine said in an 8-K that it completed its acquisition of Soleno Therapeutics on May 18, 2026 through a merger after a cash tender offer. The agreement signed April 5, 2026 set the offer price at $53.00 per share. About 88.9% of Soleno shares had been tendered when the offer expired on May 15, 2026. Soleno continues as a wholly owned subsidiary. [Neurocrine 8-K filed 2026-05-18](https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm)
2. 2026-03-06 Class action Securities class action filed against Soleno, now a Neurocrine subsidiary Neurocrine reported in its 10-Q that on March 6, 2026 the City of Pontiac Police and Fire Retirement System, a purported Soleno stockholder, filed a putative class action in the U.S. District Court for the Northern District of California against Soleno and certain managers. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act for a class period of March 26, 2025 through November 4, 2025. A lead plaintiff was appointed June 25, 2026, and defendants' motion to dismiss is due October 30, 2026. U.S. District Court for the Northern District of California · Status: pending [Neurocrine 10-Q filed 2026-07-31](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm)
3. 2025-10-28 Regulatory Neurocrine discloses DOJ civil investigative demand on Ingrezza marketing In its 10-Q filed October 28, 2025, Neurocrine disclosed that in August 2025 it received a civil investigative demand from the U.S. Department of Justice. The demand requests documents and information related to the company's sales and marketing of Ingrezza. Neurocrine says it is cooperating and that no assurance can be given on the timing or outcome of the investigation. The 10-Q filed 2026-07-31 repeats the disclosure. Status: pending [Neurocrine 10-Q filed 2025-10-28](https://www.sec.gov/Archives/edgar/data/914475/000091447525000181/nbix-20250930.htm)
4. 2025-05-05 Litigation Neurocrine sues Zydus over generic Ingrezza Sprinkle application In its 10-Q filed May 5, 2025, Neurocrine disclosed that in March 2025 it received notice that Zydus Lifesciences Global FZE had filed an ANDA for a generic version of Ingrezza Sprinkle with a Paragraph IV certification. Neurocrine filed suit in the U.S. District Court for the District of Delaware in April 2025 against Zydus entities. The 10-Q filed 2026-07-31 describes the Delaware case as continuing. U.S. District Court for the District of Delaware · Status: pending [Neurocrine 10-Q filed 2025-05-05](https://www.sec.gov/Archives/edgar/data/914475/000091447525000100/nbix-20250331.htm)
5. 2024-10-31 Financing Neurocrine enters $300 million accelerated share repurchase Neurocrine said in an 8-K that on October 31, 2024 it entered into an accelerated share repurchase agreement with Goldman Sachs & Co. LLC to repurchase an aggregate of $300.00 million of its common stock. The transaction is being completed under a previously announced $300.00 million repurchase program authorized by the board. The final share count depends on volume-weighted average prices during the term of the agreement. [Neurocrine 8-K filed 2024-11-01](https://www.sec.gov/Archives/edgar/data/914475/000091447524000214/nbix-20241031.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Ingrezza (valbenazine) | Tardive dyskinesia; chorea associated with Huntington's disease | Marketed; $716 million net sales in Q2 2026; 2026 guidance $2.825 to $2.875 billion [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) |
| Crenessity (crinecerfont) | Classic congenital adrenal hyperplasia | Marketed; $184 million net sales in Q2 2026; Phase 2 started in children aged 3 months to under 4 years [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) |
| Vykat XR (diazoxide choline) | Hyperphagia in Prader-Willi syndrome | Marketed; acquired with Soleno on May 18, 2026; $54 million net sales from closing [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) |
| Osavampator | Major depressive disorder | Phase 3; readout expected in 2027 [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) |
| Direclidine | Schizophrenia (adults) | Phase 3; readout expected in 2027 [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) |
| NBI-1117570 (dual M1/M4 agonist) | Schizophrenia (adults) | Phase 2; first patients dosed in Q1 2026 [Source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/q1-2026xearningsrelease.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Neurocrine's growth story holds up, but the results release leaves out the DOJ inquiry and leans on non-GAAP and post hoc framing

The revenue and guidance figures in the Q2 release match the 10-Q. What the release did not mention is more notable: a DOJ civil investigative demand about Ingrezza marketing and a securities class action against Soleno that Neurocrine inherited, both described in the 10-Q. Non-GAAP net income is roughly double GAAP, and the tardive dyskinesia data cited is a post hoc look at an open-label safety study.

1. Legal and disclosure record · weight high DOJ civil investigative demand on Ingrezza is in the 10-Q, not the release **The record says:** "In August 2025, we received a civil investigative demand from the U.S. Department of Justice (DOJ) requesting certain documents and information related to our sales and marketing of INGREZZA. We are cooperating with the DOJ's request. No assurance can be given as to the timing or outcome of the DOJ's investigation." The same note describes a putative class action against Soleno, now a Neurocrine subsidiary, filed on March 6, 2026 in the U.S. District Court for the Northern District of California under Sections 10(b) and 20(a), with a class period of March 26, 2025 through November 4, 2025, and a motion to dismiss due October 30, 2026. [source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm) **Our view:** Neither matter appears in the Q2 results release. The Ingrezza inquiry touches the company's largest product, at $716 million in the quarter, and the filing gives no timeline. The Soleno suit predates the acquisition and names Soleno and its managers, according to the filing.
2. Press release vs filing · weight low Non-GAAP net income is about double GAAP in the quarter **The company said:** "Second-quarter 2026 Non-GAAP net income and earnings per share were $297 million and $2.85, respectively, compared with $166 million and $1.65, respectively, for second-quarter 2025." [source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) **The record says:** GAAP net income for the quarter was $144 million. The release says the non-GAAP figures exclude "non-cash stock-based compensation expense, amortization expense related to acquired intangible assets, amortization expense related to acquisition-date inventory fair value step-up" and "acquisition-related transaction and integration costs", among other items. The release also says the company "recorded approximately $2.2 billion of intellectual property related to VYKAT XR to the balance sheet, which will be amortized over an expected life of 16 years". [source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) **Our view:** The reconciliation is in the release, so this is a framing point rather than an omission. A quarter with an acquisition inflates the gap, but stock compensation is excluded every period, and the new VYKAT intangible will keep GAAP earnings below non-GAAP for years.
3. Press release vs filing · weight medium Cash fell sharply after Soleno, which the headline figures do not show **The company said:** "Total revenues for the second quarter 2026 were $959 million, compared with $688 million in the prior-year period representing 39% year-over-year growth." [source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) **The record says:** The 10-Q says "Cash paid for the acquisition, net of cash acquired, was approximately $2.36 billion and was funded from available liquidity". It also lists a risk factor: "We may not successfully integrate Soleno Therapeutics. Inc. (Soleno) or realize the anticipated benefits of the acquisition. which could adversely affect our business and financial condition." [source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm) **Our view:** Revenue growth of 39% includes only about six weeks of VYKAT XR ($54 million), and the release adds a pro forma figure of $998 million. The $1.0 billion undrawn credit line is the backstop after cash dropped from $2.54 billion to $481.7 million, per the company's own figures.
4. Science · weight low The tardive dyskinesia data cited is post hoc, from an open-label safety study **The company said:** "Announced new post-hoc data from the KINECT ® 4 clinical trial demonstrating that adults with tardive dyskinesia treated with INGREZZA capsules experienced clinically meaningful and robust improvements in involuntary movement severity, including those who did not meet the stringent symptomatic remission threshold." [source](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) **The record says:** ClinicalTrials.gov lists KINECT 4 as a single-group, non-randomized study with masking "NONE" and 167 participants. Its one primary outcome is "Number of Participants Monitored for Long-Term Safety of Valbenazine". [source](https://clinicaltrials.gov/api/v2/studies/NCT02405091) **Our view:** A post hoc analysis of an open-label safety study cannot show efficacy against placebo. It may help prescribers, but it should not be read as new proof of benefit.

Documents we compared

- [Q2 2026 earnings release (8-K exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm) 2026-07-30
- [Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm) 2026-07-31
- [ClinicalTrials.gov NCT02405091 (KINECT 4)](https://clinicaltrials.gov/api/v2/studies/NCT02405091) 2026-10-23

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NBIX on TradingView](https://www.tradingview.com/symbols/NASDAQ-NBIX/).

## SEC filings and registration

- **SEC name**: Neurocrine Biosciences Inc

- **CIK**: 914475

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: NBIX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130

- **Phone**: (858) 617-7600

- **Shares outstanding**: 101,649,181 as of 2026-07-22 (10-Q filed 2026-07-31)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm) filed 2026-09-28
- [10-Q](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm) filed 2026-07-31
- [8-K](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/nbix-20260730.htm) filed 2026-07-30
- [8-K](https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/nbix-20260527.htm) filed 2026-05-28
- [8-K](https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm) filed 2026-05-18
- [10-Q](https://www.sec.gov/Archives/edgar/data/914475/000091447526000026/nbix-20260331.htm) filed 2026-05-05
- [8-K](https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/nbix-20260505.htm) filed 2026-05-05
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/914475/000091447526000015/nbix-20260415.htm) filed 2026-04-15

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000914475), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/neurocrine-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Neurocrine Biosciences (NBIX): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/neurocrine-biosciences/